Dovitinib is a small-molecule multi-targeted receptor tyrosine kinase inhibitor. Dovitinib inhibited Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 with IC50 values of 150nM and 90nM, respectively. The phosphorylation of each fusion gene, ERK, and STAT5 was inhibited as well at the same time. Dovitinib treatment also inhibited proliferation and survival of the FGFR1OP2-FGFR1-positive KG1 and KG1A cell lines and resulted in cell apoptosis. Furthermore, Dovitinib significantly inhibited the survival of primary cells from 8p11 myeloproliferative syndrome (EMS) patients dose-dependently.